UK markets closed

Ambu A/S (AMBU-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
136.65-0.10 (-0.07%)
At close: 04:59PM CEST
Full screen
Previous close136.75
Open137.25
Bid136.30 x 0
Ask136.60 x 0
Day's range134.75 - 139.10
52-week range65.62 - 139.90
Volume630,484
Avg. volume534,172
Market cap36.39B
Beta (5Y monthly)0.74
PE ratio (TTM)99.02
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date15 Dec 2021
1y target estN/A
  • Globe Newswire

    GRANT OF PERFORMANCE SHARE UNITS

    Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 172,956 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2023/24 have been granted on 6 February 2024 with retroactive effect from 1 January 2024. 49,109 of the PSUs have been granted to the Executive Management and 123,847 of the PSUs have been granted to other key employees. The LTIP covers the financial year 2023/24, and the final allocation of PSUs is conditional upon achievement of two key

  • GlobeNewswire

    INTERIM REPORT FOR Q1 2023/24

    In Q1 2023/24, Ambu delivered 14% organic revenue growth and a 10.0% EBIT margin before special items. This was driven by Endoscopy Solutions growing 25%, due to continued high double-digit growth within urology and ENT, combined with pulmonology growing 18%. “I am pleased with the performance within the first quarter of the year, showcasing our continued commitment to delivering strong profitable growth. With 25% growth in Endoscopy Solutions, an increased profitability level and a positive fre

  • GlobeNewswire

    ANNUAL REPORT 2022/23 (EARNINGS RELEASE)

    For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high double-digits, as well as pulmonology contributing positively, with a strengthened offering. As a result of Ambu’s focused execution, the company delivered an EBIT margin of 6.3%, mainly driven by revenue growth and reduced operational costs in distribution and staff, as well as a positive free cash